Table 3.

Life expectancy, discounted costs, discounted QALYS and ICURs for all surveillance strategies^*

Strategy	Life expectancy, y	Discounted costs, $	Discounted QALYs	Comparator	Cost difference, $	QALY difference	ICUR, $
Annual MAM beginning at age 30 years	45.73	32 643	24.419	—	—	—	—
Annual MAM beginning at age 25 years	45.76	33 331	24.435	Annual mammography beginning at age 30 years	688	0.016	43 000
Annual MRI beginning at age 30 years	45.86	38 494	24.458	Annual mammography beginning at age 25 years	5163	0.023	224 478†
Annual MRI beginning at age 25 years, switch to annual MAM at age 50 years	45.86	38 659	24.471	Annual mammography beginning at age 25 years	5328	0.036	148 000
Annual MRI beginning at age 25 years	45.90	40 704	24.480	Annual MRI beginning at age 25, switch to annual mammography at age 50 years	2045	0.009	227 222
Annual MAM and MRI beginning at age 30 years	45.88	40 932	24.467	Annual MRI beginning at age 25 years	229	−0.013	Dominated‡
Annual MRI beginning at age 25 years, addition of annual MAM at age 50 years	45.89	41 475	24.472	Annual MRI beginning at age 25 years	771	−0.008	Dominated‡
Annual MAM and MRI beginning at age 25 years	45.90	43 739	24.477	Annual MRI beginning at age 25 years	3035	−0.003	Dominated‡

^*All values are discounted to time period 1, when simulated women are aged 25 years. QALYs and Discounted QALYs report QALYs remaining after age 25 years. ICUR = incremental cost utility ratio; QALY = quality-adjusted life-year; MAM = mammography; MRI = magnetic resonance imaging.

^†Indicates strategies that can be eliminated via the principle of extended dominance. Extended dominance is applied in incremental cost-effectiveness analysis to eliminate from consideration strategies whose costs and benefits are improved by a mixed strategy of two other alternatives.

^‡”Strongly dominated” indicates a strategy that is more expensive and produces less benefit than its comparator, resulting in a negative ICUR, which is not standardly reported.